First Quarter 2019 Summary
– Oncology gross orders grew 16% in dollars, or 17% in constant currency
– Total company revenues grew 9% in dollars, or 10% in constant currency, to $741 million
– GAAP operating earnings grew 11% at 18.2% of revenues; Non-GAAP operating earnings
declined 5% at 16.2% of revenues
– GAAP net earnings per diluted share of $1.12; Non-GAAP net earnings per diluted share of
$1.06
– Recently enacted US/China tariffs negatively impacted revenues by $8 million and operating
earnings by $11 million, generally in line with company expectations
– Reaffirming fiscal year 2019 guidance of Non-GAAP net earnings per diluted share range of
$4.60 to $4.75
